The pharmacology of second-generation chimeric antigen receptors
Crossref DOI link: https://doi.org/10.1038/nrd4597
Published Online: 2015-07-01
Published Print: 2015-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
van der Stegen, Sjoukje J. C.
Hamieh, Mohamad
Sadelain, Michel
Text and Data Mining valid from 2015-07-01
Article History
First Online: 1 July 2015
Competing interests
: M.S. is scientific co-founder of Juno Therapeutics. All other authors declare no conflict of interest.